545 related articles for article (PubMed ID: 15464043)
1. Calcitonin gene-related peptide and its role in migraine pathophysiology.
Arulmani U; Maassenvandenbrink A; Villalón CM; Saxena PR
Eur J Pharmacol; 2004 Oct; 500(1-3):315-30. PubMed ID: 15464043
[TBL] [Abstract][Full Text] [Related]
2. Effects of the calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS on alpha-CGRP-induced regional haemodynamic changes in anaesthetised rats.
Arulmani U; Schuijt MP; Heiligers JP; Willems EW; Villalón CM; Saxena PR
Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):291-7. PubMed ID: 15228501
[TBL] [Abstract][Full Text] [Related]
3. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs.
Villalón CM; Olesen J
Pharmacol Ther; 2009 Dec; 124(3):309-23. PubMed ID: 19796656
[TBL] [Abstract][Full Text] [Related]
4. Determinants of 1-piperidinecarboxamide, N-[2-[[5-amino-l-[[4-(4-pyridinyl)-l-piperazinyl]carbonyl]pentyl]amino]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl) (BIBN4096BS) affinity for calcitonin gene-related peptide and amylin receptors--the role of receptor activity modifying protein 1.
Hay DL; Christopoulos G; Christopoulos A; Sexton PM
Mol Pharmacol; 2006 Dec; 70(6):1984-91. PubMed ID: 16959943
[TBL] [Abstract][Full Text] [Related]
5. [CGRP antagonists: novel concept for treatment of migraine].
Nieber K
Med Monatsschr Pharm; 2009 May; 32(5):182-5. PubMed ID: 19469188
[TBL] [Abstract][Full Text] [Related]
6. Neuropeptide effects in the trigeminal system: pathophysiology and clinical relevance in migraine.
Messlinger K; Fischer MJ; Lennerz JK
Keio J Med; 2011; 60(3):82-9. PubMed ID: 21979827
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of the non-peptide CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: potential implications in acute migraine treatment.
Moreno MJ; Abounader R; Hébert E; Doods H; Hamel E
Neuropharmacology; 2002 Mar; 42(4):568-76. PubMed ID: 11955527
[TBL] [Abstract][Full Text] [Related]
8. Effects of BIBN4096BS on cardiac output distribution and on CGRP-induced carotid haemodynamic responses in the pig.
Kapoor K; Arulmani U; Heiligers JP; Willems EW; Doods H; Villalón CM; Saxena PR
Eur J Pharmacol; 2003 Aug; 475(1-3):69-77. PubMed ID: 12954361
[TBL] [Abstract][Full Text] [Related]
9. Binding properties of the novel, non-peptide CGRP receptor antagonist radioligand, [(3)H]BIBN4096BS.
Schindler M; Doods HN
Eur J Pharmacol; 2002 May; 442(3):187-93. PubMed ID: 12065071
[TBL] [Abstract][Full Text] [Related]
10. Development of CGRP antagonists for the treatment of migraine.
Doods H
Curr Opin Investig Drugs; 2001 Sep; 2(9):1261-8. PubMed ID: 11717813
[TBL] [Abstract][Full Text] [Related]
11. Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion.
Zhang Z; Winborn CS; Marquez de Prado B; Russo AF
J Neurosci; 2007 Mar; 27(10):2693-703. PubMed ID: 17344407
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of calcitonin gene-related peptide receptors in rat atrium and vas deferens: evidence for a [Cys(Et)(2, 7)]hCGRP-preferring receptor.
Wu D; Eberlein W; Rudolf K; Engel W; Hallermayer G; Doods H
Eur J Pharmacol; 2000 Jul; 400(2-3):313-9. PubMed ID: 10988349
[TBL] [Abstract][Full Text] [Related]
13. Clinical data on the CGRP antagonist BIBN4096BS for treatment of migraine attacks.
Edvinsson L
CNS Drug Rev; 2005; 11(1):69-76. PubMed ID: 15867953
[TBL] [Abstract][Full Text] [Related]
14. Calcitonin gene-related peptide (CGRP) antagonists: blockers of neuronal transmission in migraine.
Brain SD
Br J Pharmacol; 2004 Aug; 142(7):1053-4. PubMed ID: 15237096
[TBL] [Abstract][Full Text] [Related]
15. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
Hargreaves R; Olesen J
Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist.
Doods H; Hallermayer G; Wu D; Entzeroth M; Rudolf K; Engel W; Eberlein W
Br J Pharmacol; 2000 Feb; 129(3):420-3. PubMed ID: 10711339
[TBL] [Abstract][Full Text] [Related]
17. Characterization and effects on cAMP accumulation of adrenomedullin and calcitonin gene-related peptide (CGRP) receptors in dissociated rat spinal cord cell culture.
Takhshid MA; Poyner DR; Chabot JG; Fournier A; Ma W; Zheng WH; Owji AA; Quirion R
Br J Pharmacol; 2006 Jun; 148(4):459-68. PubMed ID: 16702994
[TBL] [Abstract][Full Text] [Related]
18. Noncompetitive antagonism of BIBN4096BS on CGRP-induced responses in human subcutaneous arteries.
Sheykhzade M; Lind H; Edvinsson L
Br J Pharmacol; 2004 Dec; 143(8):1066-73. PubMed ID: 15477223
[TBL] [Abstract][Full Text] [Related]
19. Pain pharmacology in migraine: focus on CGRP and CGRP receptors.
Benemei S; Nicoletti P; Capone JA; Geppetti P
Neurol Sci; 2007 May; 28 Suppl 2():S89-93. PubMed ID: 17508187
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine.
Salvatore CA; Hershey JC; Corcoran HA; Fay JF; Johnston VK; Moore EL; Mosser SD; Burgey CS; Paone DV; Shaw AW; Graham SL; Vacca JP; Williams TM; Koblan KS; Kane SA
J Pharmacol Exp Ther; 2008 Feb; 324(2):416-21. PubMed ID: 18039958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
